

1652

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

27

Application Number

09/840,762

Filing Date

April 23, 2001

First Named Inventor

Vreeland, Valerie

Group Art Unit

1652

Examiner Name

PATTERSON, CHARLES L. JR.

Attorney Docket Number

023070-087120US

TECH CENTER 1600/2900

OCT 03 2002

RECEIVED

ENCLOSURES (check all that apply)

☐ Fee Transmittal Form☐ Fee Attached☒ Amendment / Reply☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☐ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Response to Missing Parts/ Incomplete Application☐ Response to Missing Parts under 37 CFR 1.52 or 1.53☐ Assignment Papers (for an Application)☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a Provisional Application☐ Power of Attorney, Revocation Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CO, Number of CO(s)☐ After Allowance Communication to Group☐ Appeal Communication to Board of Appeals and Interferences☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s) (please identify below):

Response to Office Action mailed June 24, 2002: Amendment (7 pages); Appendix A, Version with Markings to Show Changes Made (1 page); Appendix B, Claims Subject to Examination (2 pages); Exhibit A, Boehringer Mannheim product information manual (3 pages); Exhibit B, Invitrogen product information on Gateway vectors (3 pages); Exhibit C, Invitrogen product information on Gateway vectors (2 pages); Exhibit D, Roche product information on MBP fusion vectors (6 pages); Exhibit E, Invitrogen product information on EKMex and EK-Away (2 pages); and Return Postcard

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name

Townsend and Townsend and Crew LLP

Kevin Bastian

Reg. No. 34,774

Signature

Date

September 24, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Box Non-Fee Amendment, Commissioner for Patents, Washington, D.C. 20231 on this date:

September 24, 2002

Typed or printed name

Jill R. Clarke

Signature

Date

September 24, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1388992 v1

8/13
DMJ
18-8-02



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Non-Fee Amendment, Assistant Commissioner for Patents, Washington, O.C. 20231

PATENT
Attorney Docket No.: 023070-087120US
Client Ref. No.: 98-005-2

On September 24, 2002

TOWNSENO and TOWNSENO and CREW LLP

By: Jill R. Clarke
Jill R. Clarke

RECEIVED
OCT 03 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

VREELAND, Valerie

Application No.: 09/840,762

Filed: April 23, 2001

For: RECOMBINANT VANADIUM
HALOPEROXIDASES AND THEIR
USES

Examiner: PATTERSON, CHARLES
L., JR

Art Unit: 1652

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed June 24, 2002, please amend the claims as follows. Applicants respectfully request that the Examiner reconsider the claims in the light of the amendment and the following remarks. Appendix A is a marked-up version showing all changes made. Appendix B shows all claims subject to examination after entry of the present amendment.

IN THE CLAIMS:

Please cancel claims 18 and 19.

Please substitute claim 16 with the following clean, amended version:

16. (Amended) An isolated polypeptide comprising an amino acid sequence having at least 90% amino acid sequence identity to a sequence from residue

B1